American Heart Association

clinical trials

VITALITY-HFpEF: Designed to test the hypothesis that vericiguat may improve physical functioning in patients with HFpEF

Contributor: Emily Cendrowski

VITALITY-HFPEF is a trial underway which will evaluate the efficacy of vericiguat in HFpEF patients by using the KCCQ-PLS (Kansas City Cardiomyopathy Questionnaire Physical Limitation Score) as a primary endpoint. The choice of this primary endpoint will make it the first HF trial utilizing a quality of life, patient-reported outcome (PRO) as a primary endpoint. There remains a need for medications which improve mortality and functional status for patients with HFpEF. An ongoing area of research involves the cyclic guanosine monophosphate (cGMP) pathway.

NT-proBNP is more predictive of unfavorable outcomes in HFpEF in the absence of AFib

Contributor: Martin Chacon

Does an increased NT-proBNP in patients with atrial fibrillation (AF) and HFpEF correspond to a higher risk for worse outcomes? Kristensen et al suggest increased NTproBNP levels do not show the same correlation with poor outcomes in patients with AF compared with those without AF. NT-proBNP is increased in AF patients independently from heart failure, therefore, its capacity to predict cardiovascular death or hospitalizations in HFpEF may be diminished.

Visual Abstract: Cardiac Troponin I and Cardiac Events in HFpEF Patients

Contributor: Ike Chinyere

Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction

Study Link: Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction

Visual Abstract: Spironolactone Reduces Albuminuria in HFpEF

Contributor: Ike Chinyere

Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction The TOPCAT Trial

Study Link: Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial

Slow Adoption and Low Adherence of Sacubitril/Valsartan for HFrEF

Contributor: Nick Hawkes

PARADIGM – HF demonstrated that Sacubitril/Valsartan reduces morbidity and mortality in patients with HFrEF compared to ACE-I/ARB therapy, so why is its adoption in the real world delayed?

Sangaralingham et al. accessed data from OptumLabs Data Warehouse, a large database of de-identified medical and pharmacy claims. Among patients identified based on systolic HF ICD codes, those prescribed sacubitril/valsartan were compared to those who were not. Patient variables included health plan, age, gender, race, region, comorbidities, other prescription medications, and provider specialty. Additionally the costs, out-of-pocket (OOP) and to the health plan, were captured.